• Species Reactivity

  Human

• Specificity

  Detects human KLK-B1 in direct ELISAs.    
   

• Source

  Monoclonal Mouse IgG    _2A Clone # 736811

• Purification

  Protein A or G purified from hybridoma culture supernatant

• Immunogen

  NS0 mouse myeloma cell line transfected with human KLK-B1    
  Gly20-Ala638    
  Accession # P03952

• Formulation

  Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS.

• Label

  Unconjugated

Applications

• Recommended    
  Concentration

  Sample

• Immunohistochemistry

  8-25 μg/mL

  See below

• 
  

Please Note: Optimal dilutions should be determined by each laboratory for each application.  are available in the Technical Information section on our website.

Data Examples

Preparation and Storage

• Reconstitution

  Reconstitute at 0.5 mg/mL in sterile PBS.

• Shipping

  The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

• Stability & Storage

  Use a manual defrost freezer and avoid repeated freeze-thaw cycles.    

• 12 months from date of receipt, -20 to -70 °C as supplied.

• 1 month, 2 to 8 °C under sterile conditions after reconstitution.

• 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Plasma Kallikrein/KLKB1

Human Plasma Kallikrein, a serine protease, is synthesized in the liver and circulates in the plasma by binding to high molecular weight (HMW) kininogen or as a free zymogen. Once activated by its physiological activator, factor XII, it displays endopeptidase activity towards peptide bonds after arginine (preferred) and lysine. It cleaves HMW kininogen, its major physiological substrate, to release the potent vasodilator peptide bradykinin. It is also able to cleave a number of inactive precursor proteins to generate active products, such as plasminogen and prourokinase. Thus, it plays an important role in blood pressure regulation, fibrinolysis, and neutrophil activation (1). Human Plasma Kallikrein precursor contains a signal peptide (residues 1 to 19) and a pro form sequence (residues 20 to 638). Upon activation, the pro form is converted to a heavy chain and a light chain, which is linked by disulfide bonds and the latter contains the catalytic domain (2). The human Plasma Kallikrein pro form was expressed in the NS0 cells with a foreign signal peptide. The purified enzyme is mainly the pro form. When activated by thermolysin, it displays activity against a fluorogenic peptide substrate as described in Activity Assay Protocol. This activity can be inhibited by Human Serpin G1/C1 Inhibitor (Catalog # ).

• References:

1. Coleman, R. (2004) in Handbook of Proteolytic Enzymes, Barrett, A.J. et al. (eds.) p. 1644, Academic Press, San Diego.
   

2. Chung, N.W. et al. (1986) Biochemistry 25:2410.

• Entrez Gene IDs:

  3818 (Human); 16621 (Mouse)

• Alternate Names:

  EC 3.4.21; EC 3.4.21.34; Fletcher factor; kallikrein B, plasma (Fletcher factor) 1; kininogenin; KLK3plasma kallikrein; KLKB1; plasma kallikrein heavy chain; plasma kallikrein light chain; Plasma Kallikrein; Plasma Prekallikrein; PPK